Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Malaria vaccine development: The Plasmodium falciparum serine repeat antigen
International Conference & Exhibition on Vaccines & Vaccination
22-24 Nov 2011 Philadelphia Airport Marriott, USA

Toshihiro Horii

Scientific Tracks Abstracts: J Vaccines Vaccin


One of the most important parasitic diseases, malaria, caused by Plasmodium falciparum, has persisted and fl ourished despite global eff orts to address the disease. Undoubtedly, vaccination is a key tool for malaria control and eradication. Th e development of an eff ective vaccine, however, remains elusive. Serine repeat antigen 5 (SERA5), is a member of a multigene family in Plasmodium . SERA5 was demonstrated to be essential for parasite survival and is believed to mediate parasite egress from the infected erythrocyte. Being an abundant, exported late-trophozoite and schizont-stage protein of P. falciparum , SERA5 induced antibodies that either off ered protection against blood stage infection in vivo or inhibited parasite growth in vitro. Inhibition of proteolytic processing results in a block of parasite release from the host. Epidemiological studies show good correlation of anti-SERA antibodies to malaria protection against severe disease or fever and parasitemia. In its path towards clinical development a codon optimized recombinant protein, SE36, was obtained in large amounts suitable under Good Laboratory Practice (GLP) and has undergone preclinical studies for safety and immunogenicity. In 2005, a randomized, single-blind, placebo-controlled Phase-1a clinical trial of SE36 was undertaken in healthy Japanese adult volunteers. Th ree subcutaneous administrations of two doses were not diff erent in terms of safety, although those administered with 100  g-SE36 attained their plateau antibody titers before third administration. Age de-escalation Phase-1b trial was done in a malaria endemic area of Northern Uganda during April 2010-Feb 2011. Here, recent advancement in the development of P . falciparum malaria vaccine candidate serine repeat antigen will be presented.

Biography :

Prof. Toshihiro Horii is the Director of the Research Center for Infectious Disease Control and International Research Center for Infectious Diseases, Research Institute for Microbial Diseases (RIMD) of Osaka University. Also, a Professor of the Department of Molecular Protozoology, his group has undertaken novel studies on several aspects of P. falciparum biology including the vaccine candidate, serine repeat antigen SE-36. Work with SE-36 is a collaborative effort of RIMD (Nirianne Marie Palacpac, Ken J. Ishii), BIKEN (Hiroki Shirai, Nahoko Suzuki, Takuya Okada, Tetsutani Kohhei, Shigeharu Ueda), and MBL (Adoke Yeka, Edward Ntege, Thomas Egwang for the BK-SE36 Uganda Trial Team).